Core Viewpoint - Corcept Therapeutics Incorporated is facing a class action lawsuit for alleged violations of securities laws, specifically for making false and misleading statements regarding its product candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept misled investors by stating that relacorilant was "approaching approval" despite receiving warnings from the FDA about insufficient clinical data [1]. - The deadline for shareholders to participate in the lawsuit is April 21, 2026 [1]. - The class action is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. Group 2: Company Background - Corcept Therapeutics is publicly traded on NASDAQ under the ticker symbol CORT [1]. - The company is accused of making materially misleading public statements throughout the class period, which could have significant implications for its stock value and investor trust [1].

Core Viewpoint - Snowflake Inc. is facing a class action lawsuit for alleged violations of securities laws, specifically for making false and misleading statements regarding its financial performance and operational challenges [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from June 27, 2023, to February 28, 2024, with a deadline for participation set for April 27, 2026 [1]. - The complaint alleges that Snowflake's pricing changes and efficiency gains by customers negatively impacted its consumption levels and revenues, while the company continued to make optimistic claims about its future performance [1]. Group 2: Implications for Shareholders - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group regarding potential lead plaintiff appointments, although such appointments are not necessary to recover losses [1]. - The lawsuit highlights the potential for significant financial implications for shareholders who may have suffered losses due to the alleged misleading statements made by the company [1].

Prediction markets are exploding into mainstream chatter, and while Kalshi and Polymarket grab headlines, publicly traded plays may be the smarter way to invest in the boom.Prediction markets have ballooned from a niche corner of finance into a $63.5 billion trading volume phenomenon in 2025 alone, a fourfold increase from the prior year. Platforms like Kalshi and Polymarket are actively capturing headlines and market share, but neither is publicly traded... yet.If you want to ride this wave through the sto ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in relation to investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website discusses the high risks associated with cryptocurrencies and CFDs, highlighting that they are complex instruments with a significant potential for financial loss [1]. - It encourages users to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1].

The S&P/ASX 200 closed up on Friday (February 27, 2026), gaining 23.30 points, or 0.25%, to 9,198.60, as According to the ASX website, the top-performing stocks in this index were BLOCK, INC. and LYNAS RARE EARTHS LIMITED, up 27.83% and 10.09%, respectively. Over the last five days, the index has gained 1.29% and is currently 0.05% off of its 52-week high.The broader index rose ⁠0.3%, taking its February gain to 3.5%. The benchmark hit three record highs during the month, most recently touching 9,202.90.S& ...

everythingpossible/iStock via Getty Images Dear Baron International Growth Fund Shareholder, Performance Baron International Growth Fund® (the Fund) retreated 2.96% (Institutional Shares) during the fourth quarter of 2025, while its primary benchmark, the MSCI ACWI ex USA Index (the Benchmark), appreciated 5.05%. The MSCI ACWI ex USA IMI Growth Index (the Proxy Benchmark) gained a more modest 2.44% for the quarter. For the full year 2025, the Fund gained 21.16%, while the Benchmark appreciated 32.39% and ...

Core Insights - Serstech faced significant challenges in 2025 due to geopolitical and macroeconomic factors, particularly the impact of tariff uncertainties which led to a halt in incoming orders for over half the year [3] - Despite lower-than-expected sales, the company achieved important strategic milestones, including the full operational status of in-house production, which is expected to improve gross margins significantly in the coming years [4] - The closure of the Romanian subsidiary has resulted in lower costs and increased R&D productivity, while the company has initiated investments in artificial intelligence to enhance product performance [5] Financial Performance - Total sales for 2025 were reported at 38.6 MSEK, a decrease from 52.3 MSEK in the previous year [7] - EBITDA for 2025 was -20.9 MSEK, compared to -1.2 MSEK in 2024, indicating a substantial decline in profitability [7] - The company reported a cash flow from operating activities of -28.0 MSEK in 2025, a significant drop from 0.6 MSEK in 2024 [7] Strategic Focus - The company plans to shift its focus from R&D to sales and marketing starting in 2026, with expectations of strong and profitable growth due to a larger sales organization and improved product performance [8] - Serstech aims for an average annual sales growth exceeding 30% through 2030, with an EBITDA margin target of over 20% by 2027 [6] - The long-term goal of achieving an 80% gross margin remains unchanged, with several steps taken towards this target [4]

Sensex declined more than 600 points to 81,648, while , IndiGo, Here are some of the key factors pushing markets down today:1) FII sellingThe fall in stock markets comes as heavy selling by foreign investors may have dampened sentiment. Foreign institutional investors (FII) net sold Indian equities worth nearly Rs 3,466 crore earlier yesterday, according to data on Live Events2) Weak global marketsWall Street’s tech-heavy Nasdaq Composite index ended lower on Thursday as the tech rally failed to hold on t ...

Group 1 - The operating profit before exceptional items for the British Airways owner increased by 13.1% in 2025 [1]

>> "BLOOMBERG TECH: ASIA" IS LIVE. SHERY: 2025'S AI STORY WAS ALL ABOUT THE MAD RUSH FOR GPU'S, THE KIND MADE BY NVIDIA, BUT THE FOCUS THIS YEAR SEEMS TO BE SHIFTING TOWARD A DIFFERENT PART OF THE COMPUTER BOARD. IT IS ALL ABOUT MEMORY CHIPS.ANNABELLE: ABSOLUTELY. IN THIS EPISODE, WE WILL EXPLORE WHY IT LOOKS LIKE WE WILL NOT HAVE ENOUGH AND HOW THE CRISIS IS SPREADING BEYOND AI. FROM THE HUMBLE GAMING CONSOLE TO THE MOBILE PHONE TO OUR LAPTOPS AND EVEN THE HUGE DATA CENTERS THAT POWER AI, ALL COMPUTER SYST ...